Survival Benefits of Different Antiadrenergic Interventions in Pressure Overload Left Ventricular Hypertrophy/Failure
- 1 July 2006
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 48 (1), 93-97
- https://doi.org/10.1161/01.hyp.0000226859.42064.ea
Abstract
We observed previously that in rats with aortic banding (Bd), development of left ventricular (LV) hypertrophy is opposed by β-blockade, whereas interventions interfering with α-adrenoceptor function also inhibit interstitial fibrosis. To assess whether these differential structural effects do translate into different effects on LV function and on heart failure mortality, Bd or sham Bd 8-week–old rats were randomized to vehicle treatment (Vh), chemical sympathectomy ([Sx] 6-hydroxydopamine, 150 mg/kg IP twice a week), β-adrenoceptor blockade (propranolol [Pro], 40 mg/kg per day PO), or α-adrenoceptor blockade (doxazosin [Dox], 5 mg/kg per day PO). After monitoring survival for 10 weeks, the survivors were anesthetized to undergo echocardiography and intraarterial blood pressure measurement. Bd-Vh rats showed increased LV and lung weights, as well as LV dilation, depressed endocardial and midwall fractional shortening and a restrictive transmitral diastolic flow velocity pattern. Compared with Bd-Vh rats, all of the actively treated Bd rats showed less LV hypertrophy, LV dilation, and lung congestion but no less depression of midwall fractional shortening. In contrast, Sx and Dox but not Pro treatment were also associated with lesser degrees of diastolic dysfunction and, even more importantly, with a striking increase in survival (sham banded rats, 100%; Bd-Vh, 40%; Bd-Pro, 51%; Bd-Sx, 83%; and Bd-Dox, 82%). Although Pro, Sx, and Dox provide similar midterm protection from development of LV hypertrophy and dysfunction and from circulatory congestion, only Sx and Dox favorably affected mortality. These findings indicate that in the aortic banding rat model, α-adrenoceptors are importantly involved in the pathogenesis of cardiovascular deterioration and disease progression.Keywords
This publication has 12 references indexed in Scilit:
- Sympathectomy or Doxazosin, But Not Propranolol, Blunt Myocardial Interstitial Fibrosis in Pressure-Overload HypertrophyHypertension, 2005
- Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practiceEuropean Journal of Heart Failure, 2005
- β-Adrenergic Blockers in Heart Failure: Review of Mechanisms of Action and Clinical OutcomesJournal of Cardiovascular Pharmacology and Therapeutics, 2004
- Inhibition of left ventricular remodelling preserves chamber systolic function in pressure-overloaded micePflügers Archiv - European Journal of Physiology, 2003
- Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunitiesActa Physiologica Scandinavica, 2003
- Preservation of the Baroreceptor Heart Rate Reflex by Chemical Sympathectomy in Experimental Heart FailureCirculation, 2002
- Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of β-adrenoceptor blockadeJournal Of Hypertension, 2002
- Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2000
- Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure‐overload in the ratBritish Journal of Pharmacology, 1995
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986